Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: Single institutional experience

Patrizia Ciammella, Ala Podgornii, Maria Galeandro, Nunziata D'Abbiero, Anna Pisanello, Andrea Botti, Elisabetta Cagni, Mauro Iori, Cinzia Iotti

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Tumor control and survival have improved with the use of radiotherapy (RT) plus concomitant and adjuvant chemotherapy, but the prognosis remain poor. In most cases the recurrence occurs within 7-9 months after primary treatment. Currently, many approaches are available for the salvage treatment of patients with recurrent GBM, including resection, re-irradiation or systemic agents, but no standard of care exists.Methods: We analysed a cohort of patients with recurrent GBM treated with frame-less hypofractionated stereotactic radiation therapy with a total dose of 25 Gy in 5 fractions.Results: Of 91 consecutive patients with newly diagnosed GBM treated between 2007 and 2012 with conventional adjuvant chemo-radiation therapy, 15 underwent salvage RT at recurrence. The median time interval between primary RT and salvage RT was 10.8 months (range, 6-54 months). Overall, patients undergoing salvage RT showed a longer survival, with a median survival of 33 vs. 9.9 months (p= 0.00149). Median overall survival (OS) from salvage RT was 9.5 months. No patients demonstrated clinically significant acute morbidity, and all patients were able to complete the prescribed radiation therapy without interruption.Conclusion: Our results suggest that hypofractionated stereotactic radiation therapy is effective and safe in recurrent GBM. However, until prospective randomized trials will confirm these results, the decision for salvage treatment should remain individual and based on a multidisciplinary evaluation of each patient.

Original languageEnglish
Article number222
JournalRadiation Oncology
Volume8
Issue number1
DOIs
Publication statusPublished - Sep 25 2013

Fingerprint

Glioblastoma
Radiotherapy
Salvage Therapy
Survival
Recurrence
Adjuvant Chemotherapy
Standard of Care
Brain Neoplasms
Morbidity

Keywords

  • Acute toxicity
  • Re-irradiation
  • Recurrent glioblastoma
  • Stereotactic radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Hypofractionated stereotactic radiation therapy for recurrent glioblastoma : Single institutional experience. / Ciammella, Patrizia; Podgornii, Ala; Galeandro, Maria; D'Abbiero, Nunziata; Pisanello, Anna; Botti, Andrea; Cagni, Elisabetta; Iori, Mauro; Iotti, Cinzia.

In: Radiation Oncology, Vol. 8, No. 1, 222, 25.09.2013.

Research output: Contribution to journalArticle

@article{973ea8ffd9fe4f55bd5429db14e32ce6,
title = "Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: Single institutional experience",
abstract = "Background: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Tumor control and survival have improved with the use of radiotherapy (RT) plus concomitant and adjuvant chemotherapy, but the prognosis remain poor. In most cases the recurrence occurs within 7-9 months after primary treatment. Currently, many approaches are available for the salvage treatment of patients with recurrent GBM, including resection, re-irradiation or systemic agents, but no standard of care exists.Methods: We analysed a cohort of patients with recurrent GBM treated with frame-less hypofractionated stereotactic radiation therapy with a total dose of 25 Gy in 5 fractions.Results: Of 91 consecutive patients with newly diagnosed GBM treated between 2007 and 2012 with conventional adjuvant chemo-radiation therapy, 15 underwent salvage RT at recurrence. The median time interval between primary RT and salvage RT was 10.8 months (range, 6-54 months). Overall, patients undergoing salvage RT showed a longer survival, with a median survival of 33 vs. 9.9 months (p= 0.00149). Median overall survival (OS) from salvage RT was 9.5 months. No patients demonstrated clinically significant acute morbidity, and all patients were able to complete the prescribed radiation therapy without interruption.Conclusion: Our results suggest that hypofractionated stereotactic radiation therapy is effective and safe in recurrent GBM. However, until prospective randomized trials will confirm these results, the decision for salvage treatment should remain individual and based on a multidisciplinary evaluation of each patient.",
keywords = "Acute toxicity, Re-irradiation, Recurrent glioblastoma, Stereotactic radiation therapy",
author = "Patrizia Ciammella and Ala Podgornii and Maria Galeandro and Nunziata D'Abbiero and Anna Pisanello and Andrea Botti and Elisabetta Cagni and Mauro Iori and Cinzia Iotti",
year = "2013",
month = "9",
day = "25",
doi = "10.1186/1748-717X-8-222",
language = "English",
volume = "8",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Hypofractionated stereotactic radiation therapy for recurrent glioblastoma

T2 - Single institutional experience

AU - Ciammella, Patrizia

AU - Podgornii, Ala

AU - Galeandro, Maria

AU - D'Abbiero, Nunziata

AU - Pisanello, Anna

AU - Botti, Andrea

AU - Cagni, Elisabetta

AU - Iori, Mauro

AU - Iotti, Cinzia

PY - 2013/9/25

Y1 - 2013/9/25

N2 - Background: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Tumor control and survival have improved with the use of radiotherapy (RT) plus concomitant and adjuvant chemotherapy, but the prognosis remain poor. In most cases the recurrence occurs within 7-9 months after primary treatment. Currently, many approaches are available for the salvage treatment of patients with recurrent GBM, including resection, re-irradiation or systemic agents, but no standard of care exists.Methods: We analysed a cohort of patients with recurrent GBM treated with frame-less hypofractionated stereotactic radiation therapy with a total dose of 25 Gy in 5 fractions.Results: Of 91 consecutive patients with newly diagnosed GBM treated between 2007 and 2012 with conventional adjuvant chemo-radiation therapy, 15 underwent salvage RT at recurrence. The median time interval between primary RT and salvage RT was 10.8 months (range, 6-54 months). Overall, patients undergoing salvage RT showed a longer survival, with a median survival of 33 vs. 9.9 months (p= 0.00149). Median overall survival (OS) from salvage RT was 9.5 months. No patients demonstrated clinically significant acute morbidity, and all patients were able to complete the prescribed radiation therapy without interruption.Conclusion: Our results suggest that hypofractionated stereotactic radiation therapy is effective and safe in recurrent GBM. However, until prospective randomized trials will confirm these results, the decision for salvage treatment should remain individual and based on a multidisciplinary evaluation of each patient.

AB - Background: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Tumor control and survival have improved with the use of radiotherapy (RT) plus concomitant and adjuvant chemotherapy, but the prognosis remain poor. In most cases the recurrence occurs within 7-9 months after primary treatment. Currently, many approaches are available for the salvage treatment of patients with recurrent GBM, including resection, re-irradiation or systemic agents, but no standard of care exists.Methods: We analysed a cohort of patients with recurrent GBM treated with frame-less hypofractionated stereotactic radiation therapy with a total dose of 25 Gy in 5 fractions.Results: Of 91 consecutive patients with newly diagnosed GBM treated between 2007 and 2012 with conventional adjuvant chemo-radiation therapy, 15 underwent salvage RT at recurrence. The median time interval between primary RT and salvage RT was 10.8 months (range, 6-54 months). Overall, patients undergoing salvage RT showed a longer survival, with a median survival of 33 vs. 9.9 months (p= 0.00149). Median overall survival (OS) from salvage RT was 9.5 months. No patients demonstrated clinically significant acute morbidity, and all patients were able to complete the prescribed radiation therapy without interruption.Conclusion: Our results suggest that hypofractionated stereotactic radiation therapy is effective and safe in recurrent GBM. However, until prospective randomized trials will confirm these results, the decision for salvage treatment should remain individual and based on a multidisciplinary evaluation of each patient.

KW - Acute toxicity

KW - Re-irradiation

KW - Recurrent glioblastoma

KW - Stereotactic radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84884524096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884524096&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-8-222

DO - 10.1186/1748-717X-8-222

M3 - Article

C2 - 24066926

AN - SCOPUS:84884524096

VL - 8

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 222

ER -